Purpose The findings from the observational studies comparing the effectiveness and safety
of non–vitamin K antagonist oral anticoagulants (NOACs) versus vitamin K antagonists …

Objective Non-vitamin K antagonist oral anticoagulants (NOACs) are efficacious and safe
antithrombotic drugs but the non-availability of an antidote for potential fatal haemorrhagic …

Background Direct oral anticoagulants (DOACs) have emerged as promising alternatives to
vitamin K antagonists (VKAs) for patients with non-valvular atrial fibrillation (NVAF) or …

Aims The well-known limitations of vitamin K antagonists (VKA) led to development of new
oral anticoagulants (NOAC) in non-valvular atrial fibrillation (NVAF). The aim of this meta …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Background and Purpose: The effects of direct oral anticoagulants in nonvalvular atrial
fibrillation should be assessed in actual conditions of use. France has near-universal …

The non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly
prescribed in clinical practice for stroke prevention in patients with nonvalvular atrial …

Background and Purpose: Several observational studies have compared the effect of the
non–vitamin K antagonist oral anticoagulants to each other in patients with atrial fibrillation …

Background The original non–vitamin K antagonist oral anticoagulant (NOAC) trials in
nonvalvular atrial fibrillation (AF) enrolled patients with native valve pathologies. The object …

Atrial fibrillation (AF) and venous thromboembolism (VTE) are highly prevalent conditions
with a significant healthcare burden, and represent the main indications for anticoagulation …